- Abstract:
-
BACKGROUND: Randomised controlled trials (RCTs) of anti-EGFR monoclonal antibodies (MAb) in patients with advanced colorectal cancer (aCRC) have reported conflicting results. METHODS: A systematic review of RCTs comparing standard treatments±anti-EGFR MAbs was conducted. Hazard ratios (HR) for progression-free (PFS) and overall survival (OS) were derived for patients with wild-type (WT) and mutant KRAS. Prespecified analyses were conducted for line of treatment, MAb used, chemotherapy regimen...
Expand abstract - Publication status:
- Published
- Journal:
- Cancer treatment reviews
- Volume:
- 38
- Issue:
- 6
- Pages:
- 618-625
- Publication date:
- 2012-10-05
- DOI:
- EISSN:
-
1532-1967
- ISSN:
-
0305-7372
- URN:
-
uuid:26e1c422-db2c-4d17-af00-b11bb464eee2
- Source identifiers:
-
216464
- Local pid:
- pubs:216464
- Copyright date:
- 2012
Journal article
Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.
Actions
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record